In Vivo Model Development for Schistosomiasis

Ace Therapeutics offers a comprehensive in vivo animal model development service tailored for schistosomiasis research and therapeutic evaluation. Leveraging a diverse portfolio of validated rodent and lagomorph models, we provide end-to-end solutions for preclinical testing of anti-schistosomal compounds, vaccines, and immunotherapies. Our service is designed to deliver robust, translational data to accelerate your schistosomiasis drug discovery and development programs.

Schistosomiasis remains a major neglected tropical disease, affecting over 200 million people worldwide. Accurate and reproducible animal models are essential for elucidating disease mechanisms, evaluating novel treatment strategies, and supporting regulatory submissions. At Ace Therapeutics, we utilize a range of species and strains—primarily Mus musculus (mouse) models including Balb/c, C57BL/6, CD-1, Kunming, NMRI, NSG, Swiss, and Swiss Webster, as well as Mesocricetus auratus (golden hamster), Oryctolagus cuniculus (New Zealand White rabbit), and Rattus norvegicus (rat). These models capture key aspects of human schistosomiasis, including immune response, granuloma formation, and hepatic pathology, ensuring high relevance and predictive validity for translational research.

Infection-Induced (Helminthic) Models

This is the gold-standard approach for schistosomiasis research, involving the percutaneous or intraperitoneal infection of animals with Schistosoma spp. cercariae. The methodology allows for controlled infection load and synchronized disease progression. Key advantages include faithful recapitulation of the natural infection cycle, host immune responses, and pathophysiological changes such as granuloma formation and hepatic fibrosis. Primary research applications include drug efficacy studies, vaccine testing, immunopathogenesis analysis, and biomarker discovery.

Genetically Defined Mouse Models

Utilizing various inbred and immunodeficient mouse strains (e.g., Balb/c, C57BL/6, NSG, Swiss, NMRI), these models enable the study of host genetics and immune mechanisms in schistosomiasis. The methodology involves infecting genetically characterized mice and monitoring differential disease outcomes. Advantages include the ability to dissect genetic and immunological factors influencing disease susceptibility, chronicity, and response to therapy. Applications span immunological studies, host-pathogen interaction research, and evaluation of immunomodulatory treatments.

Alternative Host Models (Hamster, Rabbit, Rat)

In addition to mice, Ace Therapeutics offers schistosomiasis models in golden hamsters, New Zealand White rabbits, and rats. These alternative hosts are infected with Schistosoma spp. to model specific aspects of disease, such as severe hepatic pathology (hamsters) or large-scale tissue sampling (rabbits, rats). Advantages include broader host-pathogen interaction insights and suitability for certain pharmacokinetic or toxicology studies. These models are particularly valuable for cross-species validation of drug efficacy and safety.

Ace Therapeutics delivers a full-service workflow, from model selection and experimental design to infection, treatment administration, and comprehensive endpoint analysis. Key efficacy endpoints include worm burden quantification, egg count in tissues and feces, liver and spleen weight, histopathological assessment (granuloma size, fibrosis scoring), clinical chemistry, and immunological profiling (cytokine levels, antibody titers). Our analytical capabilities encompass advanced imaging, molecular assays (qPCR, ELISA), flow cytometry, and digital pathology. Stringent quality control measures are enforced at every stage—animal health monitoring, standardized infection protocols, and rigorous data validation—ensuring reproducibility and regulatory compliance.

Partnering with Ace Therapeutics means gaining access to extensive schistosomiasis modeling expertise, state-of-the-art facilities, and a collaborative approach focused on your research objectives. Our integrated service accelerates discovery timelines, reduces risk, and enhances the translational value of your preclinical data. Contact us today to discuss your schistosomiasis research needs and discover how our tailored in vivo solutions can advance your program.